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Abstract
Colony stimulating factor-1 (CSF-1 or M-CSF) is the major physiological regulator of the proliferation, differentiation and
survival of cells of the mononuclear phagocyte lineage. CSF-1 binds to a receptor tyrosine kinase, the CSF-1 receptor (CSF-
1R). Multiple pathways are activated downstream of the CSF-1R; however, it is not clear which pathways regulate
proliferation and survival. Here, we investigated the role of atypical protein kinase Cs (PKCf) in a myeloid progenitor cell line
that expressed CSF-1R (32D.R) and in primary murine bone marrow derived macrophages (BMMs). In 32D.R cells, CSF-1
induced the phosphorylation of PKCf and increased its kinase activity. PKC inhibitors and transfections with mutant PKCs
showed that optimal CSF-1-dependent Erk activation and proliferation depended on the activity of PKCf. We previously
reported that CSF-1 activated the Erk pathway through an A-Raf-dependent and an A-Raf independent pathway (Lee and
States, Mol. Cell. Biol. 18, 6779). PKC inhibitors did not affect CSF-1 induced Ras and A-Raf activity but markedly reduced MEK
and Erk activity, implying that PKCf regulated the CSF-1-Erk pathway at the level of MEK. PKCf has been implicated in
activating the NF-kB pathway. However, CSF-1 promoted proliferation in an NF-kB independent manner. We established
stable 32D.R cell lines that overexpressed PKCf. Overexpression of PKCf increased the intensity and duration of CSF-1
induced Erk activity and rendered cells more responsive to CSF-1 mediated proliferation. In contrast to 32D.R cells, PKCf
inhibition in BMMs had only a modest effect on proliferation. Moreover, PKCf -specific and pan-PKC inhibitors induced a
paradoxical increase in MEK-Erk phosphorylation suggesting that PKCs targeted a common negative regulatory step
upstream of MEK. Our results demonstrated that CSF-1 dependent Erk activation and proliferation are regulated
differentially in progenitors and differentiated cells.
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Introduction
Colony stimulating factor-1 (CSF-1 or M-CSF) is a growth
factor secreted by numerous cell types, whose synthesis is often
increased in response to different stimuli such as those causing
inflammation [1]. It promotes the proliferation, survival and
differentiation of cells of the mononuclear phagocyte (MNP)
lineage and their myeloid progenitors [1,2]. CSF-1 acts on the
CSF-1R, a receptor tyrosine kinase (RTK) of the platelet-derived
growth factor (PDGF) receptor family that also includes c-kit and
the Flt3/Flk2 receptor. CSF-1R, c-Kit and Flt3 all play pivotal
roles in hematopoiesis. The importance of CSF-1-CSF-1R
signaling in vivo is revealed by the pleiotropic functional defects
of the CSF-1 null (op/op) and CSF-1R null mice [1,2] including
deficiencies in hematopoietic progenitors, monocytes, macrophag-
es, innate immune responses, bone remodeling, mammary gland
development and fertility. CSF-1-CSF-1R signaling contributes to
the inflammatory component associated with many chronic
diseases, notably cancer, arthritis, neurodegenerative diseases,
atherosclerosis and obesity. Oncogenic signals emanating from an
aberrantly expressed CSF-1R in tumor cells promote tumor
growth and metastasis in breast and ovarian cancers [3]. A second
ligand for the CSF-1R was recently identified [4], IL-34, that has a
different spatiotemporal expression pattern from CSF-1 [5] and is
likely to regulate microglial development in the brain [6]. The
existence of IL-34 explains the milder phenotype of CSF-1 null
mice compared to mice lacking CSF-1R.
CSF-1 binding initiates dimerization of the CSF-1R and results
in kinase activation [7,8], autophosphorylation, recruitment of
signaling molecules to the receptor, and rapid stimulation of
downstream signaling. Tyrosine autophosphorylation sites
mapped in the CSF-1R are Tyr 697, Tyr 706 and Tyr 721 in
the kinase insert region that divides the catalytic domain, Tyr 807
in the activation loop of the catalytic domain, Tyr 559 in the
juxtamembrane region, and Tyr 921, Tyr 974 in the carboxy-
terminus [1,9]. Many molecules have been reported to bind these
autophosphorylation sites. Of note, Tyr 559 has a dual function:
when not phosphorylated, it has an autoinhibitory role, when
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and Tyr 921 bind Grb2 [12,13], an adaptor that is constitutively
associated with the Ras guanine nucleotide exchange factor (Sos).
Membrane localization of Ras leads to activation of the Raf-
MEK-Erk (extracellular signal regulated kinase)/MAPK (mitogen
activated protein kinase) pathway [14]. Tyr 721 binds the p85
regulatory subunit of phosphatidylinositol 3-kinase (PI3K) [15]
bringing the lipid kinase into proximity to its substrates in the
plasma membrane. Additionally, the CSF-1R recruits PI3K via an
alternate pathway involving SFKs and Gab2 [16]. Tyr 974 binds
c-Cbl [17], an E3 ubiquitin ligase important for CSF-1R
downregulation and termination of receptor signaling [18]. CSF-
1 binding also stimulates the tyrosine phosphorylation of other
molecules such as SHC and Ship [1] and together the receptor
signaling complex mediates MNP development and mature cell
function and activation.
The Ras-Raf-MEK-Erk pathway is evolutionarily conserved
and controls many aspects of cell activities [14]. We previously
showed that CSF-1 induced Erk activity is important for
supporting cell survival in a myeloid progenitor cell line, 32D.R
[19]. In these cells, A-Raf and not c-Raf-1 mediates a part of the
activating signal from the CSF-1R to the Erk kinase, MEK1; PI3K
is also upstream of MEK1 but working in parallel to A-Raf [16].
How PI3K signals to MEK1 is not clear since it is a lipid kinase
and MEK1 requires phosphorylation at two serines for activation.
Potentially, PI3K could target an inhibitor of the pathway. For
example, Raf kinase inhibitor protein (RKIP) binds to c-Raf-1 and
prevents MEK phosphorylation [14] but does not appear to affect
B-Raf activation [20] and its influence on A-Raf is unknown.
Another possibility is input from the protein kinase C (PKC) family
[21]. Members of the PKC family belong to one of three classes:
conventional (PKCa, bI, bII, c), novel (d, e, h, g) and atypical (f,
l) [22]. PKCs are regulated by a series of priming phosphoryla-
tions [22], including phosphorylation in the active site by 39-
phosphoinositide-dependent kinase-1 (PDK-1), in the turn motif
by the mTORC2 complex and in conventional and novel PKCs in
the hydrophobic motif by different kinases, including mTORC2.
These phosphorylations play important roles in stabilizing PKCs.
Conventional PKCs bind to calcium and diacylglycerol and are
recruited to the plasma membrane whereas novel PKCs bind only
to diacylglyerol; atypical PKCs do not bind either calcium or
diacyglycerol. The interactions with the plasma membrane result
in a conformational change that leads to downstream signaling. All
three PKC classes can stimulate the Erk pathway but only
conventional and novel PKCs activate MEK-Erk via c-Raf-1
whereas atypical PKCs such as PKCf use a c-Raf-1 independent
mechanism [23]. PKCf -dependent Erk activity is necessary for
NF-kB activation [24]. Depending on cell type however, PKCf
deficiency does not always result in diminished Erk activation [25].
PI3K is reported to increase PKCf activity by enhancing Thr 410
phosphorylation in a PDK-1-dependent manner [26]. Previous
work examining the role of PKCf in CSF-1 signaling had yielded
controversial findings. In one study, CSF-1 was reported to
increase the in vitro autokinase activity of a catalytic fragment of
PKCd but activated PKCf was not detected in that assay [27]. In
another study, PKCf activation by CSF-1 was assessed by
membrane translocation [28], but that may not be an adequate
indication of PKCf activation since atypical PKCs are not
dependent on diacylglcyerol generated at the membrane for
activation. Yet in a third study PKCf knockdown was found to
reduce CSF-1 induced macrophage migration [29].
Herein we tested the hypothesis that PKCf may mediate the A-
Raf independent pathway to activate MEK-Erk in response to
CSF-1 in myeloid cells: 32D.R myeloid progenitors and primary
bone marrow derived macrophages (BMMs). We found that CSF-
1 increased PKCf Thr 410 phosphorylation and kinase activity in
32D.R cells. Pharmacologic inhibition and transfection studies
demonstrated that atypical PKCs but not conventional or novel
PKCs contributed towards CSF-1 induced MEK-Erk activity in a
c-Raf-1 and A-Raf-independent fashion. While PKCf kinase
inhibition reduced CSF-1 supported mitogenesis in 32D.R cells,
overexpression of PKCf increased CSF-1 mitogenic responsive-
ness. However, PKCf’s promotion of mitogenic signaling in
32D.R cells was independent of NF-kB. In BMMs, PKCf
inhibition had a more modest effect on CSF-1 dependent
mitogenesis, and, pan-PKC inhibition had a paradoxically
enhancing effect on MEK-Erk phosphorylation. Thus the
importance of PKCf in the control of CSF-1 mediated MEK-
Erk activity and mitogenesis depends on differentiation stage.
Methods
Antibodies and reagents
Cell culture reagents and media were from Life Technologies
(Carlsbad, CA) or Sigma-Aldrich (St. Louis, MO). GF109203X
was from EMD Chemicals (Rockland, MA) or Enzo Life Sciences
(Plymouth Meting, PA), Ro-31-8220 was from Axxora (San Diego,
CA) and Go 6983 was from EMD Chemicals. Myelin basic
protein (MBP) was from Life Technologies, PKCe pseudosubstrate
peptide (residues 149–164, Ala to Ser 159) as phosphorylation
substrate and myristoylated PKCf pseudosubstrate peptide were
from Enzo Life Sciences. Recombinant human CSF-1 was a gift of
Genetics Institute (Cambridge, MA), recombinant murine inter-
leukin-3 (IL-3) was from Life Technologies, and phorbol 12-
myristate 13-actetate (PMA) was from EMD Chemicals.
Polyclonal antibodies against c-Raf-1, A-Raf, Erk2, were from
Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies against
PKCa, PKCb, PKCc, PKCd and PKCe were from Life
Technologies. We used a rabbit polyclonal antibody against
PKCf for immunoprecipitations or a monoclonal antibody for
immunoblotting (both from Santa Cruz). The following monoclo-
nal antibodies were used: MEK1 from BD Transduction Labs
(Lexington, KY), Myc (9E10) from Santa Cruz, hemagglutinin
(HA) antibody from BAbCo (Berkeley, CA), and Ras Ab-4 from
EMD Chemicals. Phosphospecific antibodies that recognize Erk or
MEK were from Cell Signaling Technology (Danvers, MA) and
an antibody that recognizes Thr 410 of PKCf was a gift from Alex
Toker (Harvard Medical School) or purchased from Santa Cruz.
Animals
A colony of C57BL/6 mice was housed in a specific pathogen-
free environment. The Animal Welfare Committee at the
University of Texas Health Science Center, Houston approved
all animal protocols (IACUC assurance number: A3413-01,
protocol number 08-131 and 09-032) and studies were carried
out in accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of
Health. Mice were sacrificed by CO2 asphyxiation followed by
cervical dislocation.
Plasmids
PKC constructs utilized in this study were as follows: PKCf (T/
A)4, obtained from Peter Parker (ICRF, London), is a dominant-
negative PKCf with ThrRAla substitutions at the activation loop
phosphorylation sites [30]; constitutively active HA-tagged PKCf,
consisting of only the catalytic domain of PKCf [31] was from
Jorge Moscat (Universidad Autonoma de Madrid, Madrid). PKC
constructs used in transient transfections were cloned into the
PKCf is an Activator of M-CSF MAPK Signaling
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wildtype PKCf was cloned into pEFIRES-puro [32]. The
construction of Myc-tagged Erk2 has been described [16]. The
NF-kB reporter plasmid (pBxVIII) containing 6 tandem kB
binding sites was obtained from Gabriel Nunez (University of
Michigan Medical School) [33].
Recombinant proteins
Recombinant bacterially-produced His-tagged kinase-dead
MAPK, MEK and GST-RBD, containing the Ras binding
domain of Raf (residues 51–131) fused to GST (plasmid generously
provided by Johannes Bos, Utrecht University, Utretcht) were
expressed and purified as described [16].
Cell culture and transfections
The IL-3-dependent myeloid progenitor cell line expressing
CSF-1R (32D.R) has been described previously [19]. A stable
32D.R cell line expressing an NF-kB luciferase reporter was
established by co-transfection with pBxVIII and pPUR (Clontech
Laboratories, Mountain View, CA) and mass populations selected
in 1 mg/mL puromycin. A stable 32D.R cell line expressing WT-
PKCf was similarly established by electroporation with pEFIRES-
p-WT- PKCf. BMMs were produced as described previously [34].
Briefly, total bone marrow cells were isolated from the femurs and
tibias of C57BL/6 mice and induced to differentiate to
macrophages over 7 days. For stimulation experiments, exponen-
tially growing 32D.R cells were washed thoroughly in Hank’s
Buffered Salt Solution and deprived of serum and IL-3 for 3 h
prior to treatment with inhibitors and growth factors. For BMMs,
on day 7, cells were thoroughly washed and starved in the absence
of CSF-1 for 12 hours. Cells were then pretreated with inhibitors
for 1 h followed by CSF-1 addition. The protocol for transient
transfection has been previously described [19] and transfected
cells were allowed to express recombinant proteins for 24 h before
starvation and analysis.
Immunoprecipitation, immunoblotting, kinase assays
and Ras activation assay
Protein analysis methods have been extensively described in
previous publications [16,19,34]. To measure the kinase activity of
PKCf, PKCf was immunoprecipitated from cell lysates and
subjected to an in vitro kinase assay in the presence of 10 mCi of
c
32P ATP, 50 mM ATP and 50 mM PKCe peptide as substrate.
Reaction proceeded for 8 min at 30uC and was spotted onto P81
phosphocellulose paper as described previously [19] 1 mM Ro-31-
8220 was included in the kinase reaction in parallel samples to
confirm the phosphorylation was due to PKCf.
32P incorporation
was quantified using a Storm PhosphorImager (Molecular
Dynamics). Immunoblots were detected using ECL or ECL plus
(GE Healthcare). To quantify band intensities on immunoblots,
multiple exposures of each blot were obtained and band intensities
determined using the NIH Image 1.43 software except where
noted in the figure legend.
Subcellular fractionation
Cells were resuspended at a density of 8610
7/ml in HB (10 mM
b-glycerophosphate pH 7.5, 10 mM KCl, 1 mM EDTA, 1 mM
EGTA, 1 mM MgCl2) supplemented with protease and phospha-
tase inhibitors and homogenized with a Dounce homogenizer until
cell breakage (monitored by phase-contrast microscopy and Trypan
Blue staining) was .90%. Nuclei and unbroken cells were removed
by centrifugation at 10006g for 5 min and the supernatant re-
centrifuged at 100,0006g for 1 hr. The supernatant was adjusted to
contain a final concentration of 0.5% NP40, 0.1% sodium
deoxycholate and 0.1% Brij35 and after spinning, designated the
S100 (cytosolic) fraction. The pellet after the 100,0006g spin was
Dounce homogenized and extracted with HB containing the above
detergents, centrifuged at 16,0006g for 15 min to remove insoluble
material and the supernatant designated the P100 fraction.
Variation in the ratio of total cytosolic to membrane protein
amongst the samples was 3% indicating equivalent fractionation
and extraction. Purity of the fractions was determined by assaying
for the activity of a cytosolic marker, lactate dehydrogenase, and for
the presence of Ras, by Western blotting. Less than 10% of the
LDH activity was found in the membrane (P100) fraction and no
Ras was detected in the cytosolic (S100) fraction (data not shown).
Proliferation assay
Proliferation was assessed using the MTS tetrazolium assay
(CellTiter 96
TMkit, Promega, Madison, WI) as described [19].
3,000 32D.R cells or 3,750 BMMs were plated in triplicate in 96
well plates in the absence or presence of inhibitors or growth
factors. MTS activity was read at 48 h unless otherwise stated. Cell
counts were performed in duplicate using a hemocytometer and
dead cells excluded with Trypan Blue.
Luciferase assay
Luciferase activity was assayed using the Luciferase Reporter
Assay (Promega). 32D.R cells stably expressing an NF-kB reporter
were washed extensively and starved in serum-free medium [19]
for 2 h before the addition of inhibitors, followed 1 h later by
5 nM CSF-1 or 20 ng/mL TNFa. Cells were harvested 6 h later.
For long-term activation, cells were starved in media without
growth factors for 6 h, before the addition of inhibitors, followed
by CSF-1 or TNFa.1 0mg (CSF-1 series) or 5 mg (TNFa) of lysate
was used and each assay performed in duplicate.
Results
Inhibition of atypical PKC activity decreases CSF-1
dependent mitogenesis in 32D.R myeloid progenitors
32D.R cells express cell surface markers (CD31
+Ly6C
+CD11b
2)
that are consistent with an immature myeloid phenotype [35] (Fig.
S1, and Methods S1). We have previously shown that Erk activity is
important for CSF-1 supported proliferation and survival in these
cells [19]. To determine if PKC has a similar role in promoting
CSF-1 mitogenesis, we first determined the expression pattern of
PKCs. 32D.R cells expressed PKCa, PKCd, PKCe and PKCf but
not PKCb or PKCc (Fig. 1A). Two bands around 70 kDa were
detected in the PKCf blot. We believe the lower band to be the
authentic PKCf protein because only the lower band was present in
A431 cells (positive control provided by the manufacturer), it was
not affected by chronic phorbol ester treatment (see later) nor
induced to translocate to the membrane (see later). Lastly, it co-
migrated with transiently overexpressed PKCf (see later).
To assess the role of PKCs in CSF-1 dependent growth we used
the MTS assay [19,34]. We tested the effect of PKC inhibitors
with different specificities: GF109203X (also known as Bisindo-
lylmaleimide I, or Go ¨ 6850) inhibits purified conventional and
novel PKCs in the nanomolar range and atypical PKCs in the
micromolar range [36]. Go ¨ 6893 inhibits purified conventional
and novel PKCs at ,10 nM and PKCf at 60 nM [37]. Ro 31-
8220 is a potent inhibitor of PKCs but has been reported to inhibit
non-PKC kinases using in vitro assays [38] although this
observation may not be applicable to intact cells [39]. The PKCf
pseudosubstrate peptide mimics the substrate binding site in PKCf
but with a non-phosphorylatable Ala in place of the target site and
PKCf is an Activator of M-CSF MAPK Signaling
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CSF-1 dependent mitogenesis with an IC50 of <7.5 mM whereas
the IC50 for Go ¨ 6983 was between 2.5 and 5 mM( Fig. 1B). At
2.5 mM, Ro-31-8220 completely prevented CSF-1 dependent
mitogenesis. At 1 mM, both GF109203X and Go ¨ 6983 should
have inhibited conventional and novel PKCs, but the reduction in
CSF-1 dependent mitogenesis was minimal. The IC50 of <7.5 mM
for GF109203X is consistent with a role for PKCf yet at the
concentration that is reported to inhibit PKCf (1 mM), Go ¨ 6983
was less potent. However published IC50 values are based on
inhibition of recombinant PKC isoenzymes and do not reflect
accessibility to intracellular stores of these enzymes, or duration of
Figure 1. The effect of PKC inhibitors on CSF-1 dependent mitogenesis. (A) PKC immunoblots. ‘‘+’’ refers to the presence of a competing
peptide. Arrow points to the PKC band that is competed off by the corresponding peptide. The lower band in the PKCf blot is the authentic PKCf
protein (see text). (B) MTS assay. 32D.R cells were plated under the conditions shown and in the presence of 5 nM CSF-1. MTS activity was assayed
after 48 h. (C) MTS assay was performed as described in (A) in the presence of the indicated amounts of PKCf pseudosubstrate peptide. (D) MTS
assay in the presence of CSF-1 and the indicated inhibitors, 10 mM U0126 and 5 mM LY294002.
doi:10.1371/journal.pone.0025580.g001
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reversibility of inhibition, half life of the inhibitor and protein
turnover. We also used a myristoylated PKCf pseudosubstrate
peptide to directly investigate the role of PKCf. A dose dependent
effect was observed and the IC50 was <20 mM, which is in the
range of what has been reported in published work [29,41]. For
Figure 2. The effect of PKC inhibitors on CSF-1 mediated Erk, MEK, Raf and Ras activation. (A, B) 32D.R cells were pretreated with the
indicated amounts of inhibitors (Inh) followed by CSF-1 stimulation for 4 min. Lysates were immunoblotted with phospho-Erk (top) or total Erk1/2
(bottom) antibody (A) or with phospho-MEK (top) and total MEK1 (bottom) antibody (B). (C) Cells were processed as described for (A, B). Inhibitors
were added at 10 mM. Lysates were immunoprecipitated with either A-Raf or Raf-1 antibody and immune complexes used in an in vitro kinase (IVK)
assay with KD-MEK as substrate. Phospho-MEK was then detected by immunoblotting. In (A–C), changes in phosphorylation are expressed as
percentages of CSF-1 mediated increase in phosphorylation over unstimulated cells, where 0% and 100% denote phosphorylation in the absence or
presence of CSF-1 without inhibitors. (D) Ras activation. Cells were starved and pretreated as indicated with Ro-31-8220 (10 mMo r3 0mM) before
stimulation with 5 nM CSF-1 for 4 min. Ras-GTP was extracted from 500 mg of lysates using the GST-RBD pull-down assay. 50 mg of total cell lysates
were also loaded for comparison.
doi:10.1371/journal.pone.0025580.g002
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respectively markedly reduced CSF-1 supported mitogenesis
(Fig. 1C, D). Collectively these results suggest the possibility that
PKCf contributes to CSF-1 dependent growth in 32D.R cells.
PKC inhibitors reduce CSF-1-stimulated MEK-Erk activity
in a pathway parallel to Raf and downstream of Ras
We have previously shown that CSF-1 stimulates the MEK-Erk
pathway by both an A-Raf dependent and A-Raf independent
pathway [16]. We hypothesized that PKC may mediate the A-Raf
independentpathway.PretreatmentwithGF109203X,Ro-31-8220
or Go ¨ 6983 all reduced CSF-1 induced Erk (Fig. 2A) and MEK
(Fig. 2B) phosphorylation. Since GF109203X inhibited MEK-Erk
activity by 49% at 10 mM but was minimally effective at 1 mM, and
Go ¨ 6983 reduced MEK-Erk activity by 90% at 1 mM, these data
implicate the contribution of atypical PKCs. The observation that
Go ¨ 6983 markedly inhibited MEK-Erk activity at 1 mM contrasted
with its effect on mitogenesis, lending credence to the suggestion
that long term effects of PKC inhibitors such as that on
proliferation, must also take into account other factors described
above, in addition to IC50 measured using purified proteins. We
then determined the effect of PKC inhibition on A-Raf and c-Raf-1
Figure 3. CSF-1-stimulated ERK activity is independent of phorbol ester-sensitive PKCs. (A) 32D.R cells were pretreated with 10 mM
GF109203X followed by 5 nM CSF-1 or 0.5 mM PMA stimulation for 4 min. Erk and MEK activity were determined in an in vitro kinase assay with
myelin basic protein (MBP) and KD-Erk as substrate respectively. (B) Exponentially growing 32D.R cells were treated with 100 nM PMA for 24 hr to
downregulate phorbol ester sensitive-PKCs and continued during the starvation period (designated as *PMA). Cells were either left untreated or
treated with 5 nM CSF-1 or 0.5 mM PMA for 4 min. An MBP kinase assay on Erk immunoprecipitates was performed. In (A) and (B), change in
phosphorylation is calculated as described in Figure 2. (C) Phorbol ester-sensitive PKCs in 32D.R. Total cell lysates were Western blotted with the
indicated anti-PKC antibodies in the absence (2) or presence (+) of the immunizing peptide.
doi:10.1371/journal.pone.0025580.g003
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Neither GF109203X nor Go ¨ 6983 significantly influenced A-Raf
activity whereas their effect was more pronounced on c-Raf-1
(Fig. 2C). However, we have previously shown that while CSF-1
stimulated c-Raf-1 activity, inhibiting c-Raf-1 had no effect on Erk
activation [16], consistent with reports that c-Raf-1 could have
other functions that are independent of MEK-Erk [42]. Lastly,
PKC inhibitors had no effect on Ras activation (Fig. 2D). These
data indicate that PKC is activating an A-Raf independent pathway
downstream of Ras to promote CSF-1 induced MEK-Erk
activation.
CSF-1-stimulated Erk activity is independent of phorbol
ester-sensitive PKCs
The inhibitor studies support a role for PKCs in mediating
CSF-1 dependent MEK-Erk activation but did not prove that it
was PKCf. We next set out to exclude an involvement of phorbol
ester-sensitive PKCs. Here we used an in vitro kinase assay to
directly assay Erk and MEK activity (Fig. 3A). Both CSF-1 and
PMA strongly induced MEK and Erk activity towards an
exogenous substrate. Whereas GF109203X was completely
inhibitory towards PMA stimulated MEK and Erk activity, in
agreement with results in Fig. 2A, it only partially reduced CSF-1
induced MEK and Erk activity. Cells were then treated with PMA
for 24 hours to downregulate PMA-sensitive PKCs, starved and
acutely stimulated with either CSF-1 or PMA. Downregulating
PMA-sensitive PKCs had no effect on CSF-1-mediated ERK
activity whereas PMA-induced ERK activity was almost com-
pletely abolished (Fig. 3B). We next determined which PKC
isoforms were susceptible to PMA downregulation (Fig. 3C).
When cells were exposed to long-term PMA treatment, PKCa and
PKCd disappeared whereas PKCe was downregulated by 34%
and there was no effect on PKCf. Thus, CSF-1-induced ERK
activity did not involve PKCa or PKCd but PKCe and PKCf
remain potential regulators of the ERK pathway.
CSF-1 stimulates PKCf kinase activity but has no effect on
PKCe translocation
Growth factor or PMA-mediated signaling to conventional and
novel PKCs can be inferred from translocation of the PKC
isoform from cytosol to membrane. We determined if CSF-1
signaled to PKCe, using a membrane translocation assay. Western
blotting of equal amounts of cytosolic and membrane fractions
showed that in unstimulated cells, PKCe was predominantly
cytosolic (Fig. 4A). Treatment with CSF-1 for 4 min, the same
conditions that induced maximal ERK activation, did not result in
PKCe translocation to the membrane. In contrast, PMA induced a
marked increase in membrane PKCe immunoreactivity. There
was no detectable translocation of PKCf to the membrane in
response to either CSF-1 or PMA. Inhibiting PKC activity with
Ro-31-8220 did not influence PMA-induced membrane translo-
cation indicating that membrane recruitment is independent of
PKC activity. Similarly, inhibiting PI3K activity with wortmannin
that would prevent PDK-1 recruitment to the membrane [43] also
had no impact. The upper band recognized by the anti- PKCf
antibody has been proposed to be PKCa by others [44]. Our
findings support this hypothesis since PMA induced membrane
localization. Curiously, this band was not completely downregu-
lated by PMA even though the PKCa immunoreactive protein
was completely degraded (Fig. 3C).
We measured activation of PKCf by an immune complex
kinase assay using the PKCe pseudosubstrate peptide as substrate.
This is reported to be the best in vitro substrate for PKCf [45,46].
Figure 4. CSF-1 increases PKCf activity but does not induce
PKCe membrane translocation. (A) Subcellular fractionation. 32D.R
cells were starved, pretreated or not with wortmannin (200 nM) or Ro-
31-8220 (30 mM) before stimulation with 5 nM CSF-1 or 0.5 mM PMA for
4 min. Homogenates were separated into cytosolic (S100) and
particulate (P100) fractions as described in Methods. 75 mg of each
fraction was analyzed by Western blotting with anti-PKCe or PKCf
antibodies. Asterisk indicates the PKCf protein. (B) CSF-1 stimulated
PKCf kinase activity in an in vitro kinase assay. Ro-31-8220 was included
in parallel experiments. (C) CSF-1 stimulated PKCf phosphorylation.
Lysates from 32D.R cells treated as indicated were immunoprecipitated
with an anti- PKCf antibody and blotted with a phospho- PKCf-T410
antibody. Phosphorylation changes are calculated as described in
Figure 2. For reference, at 4 min, CSF-1 stimulated a 7-fold increase in
T410 phosphorylation.
doi:10.1371/journal.pone.0025580.g004
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(Fig. 4B). A similar, 2-fold increase in activity was obtained using
MBP, another commonly used substrate (data not shown). When
1 mM Ro-31-8220 was included in the kinase reaction, the activity
was reduced to below basal levels. Atypical PKCs are phosphor-
ylated by PDK-1 on Thr 410 which is in the activation loop [22].
We used an antibody that detects phosphorylated Thr 410 and
found that CSF-1 significantly increased PKCf Thr 410
phosphorylation (Fig. 4C). For comparison, we also determined
that IL-3 increased PKCf Thr 410 phosphorylation, since 32D.R
cells are IL-3 dependent. Taken together, our findings support the
possibility that PKCf, rather than PKCe contributed towards
CSF-1-induced ERK activation.
Dominant-negative PKCf inhibits Erk activity stimulated
by either CSF-1 or PMA and constitutively active PKCf
activates Erk in the absence of growth factor
We further investigated the involvement of PKCf by determin-
ing the effect of transient expression of a dominant-negative PKCf
[30]. An empty vector or a PKCf construct in which four
threonines in the activation loop (including Thr 410, the PDK1
phosphorylation site) have been replaced with alanines was
Figure 5. The effect of dominant-negative and constitutively active PKCf on ERK activation. (A) Dominant-negative PKCf. 32D-CSF-1R
cells were transfected with 4 mg of HA-ERK and 10 mg of either pcDNA or PKCf (T/A)4. 24 hr later, cells were starved and stimulated with 10 nM CSF-1
or 0.5 mM PMA for 4 min. Expression of transfected proteins was confirmed by blotting with anti- PKCf (top) or anti-HA (middle) antibodies. HA
immunoprecipitates were analyzed for MBP kinase activity (bottom). Phosphorylation changes are calculated as described in Figure 2. In the
experiment shown, CSF-1 induced a 3.9-fold increase in MBP phosphorylation over unstimulated cells. Panel on the right shows the averaged results
from 3 independent transfections. Data are expressed as the mean 6 SD. (B) Constitutively active PKCf. Cells were transfected with 10 mg of Myc-ERK
and 40 mg of either pcDNA, HA-WT-PKCf or HA-PKCfcat. They were treated as described in (A). (left) PKCf in vitro kinase activity. PKCf was
immunoprecipitated using an HA antibody and subjected to an in vitro kinase activity with PKCe pseudosubstrate peptide as a substrate. Shown are
the means 6 SD (n=3). (right) Lysates containing approximately equivalent amounts of Myc-ERK were analyzed for MBP kinase activity in anti-Myc
immunoprecipitates. Basal MBP phosphorylation in cells transfected with PKCfcat was 1.8 fold over that in cells transfected with an empty vector.
doi:10.1371/journal.pone.0025580.g005
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MBP kinase activity in HA immunoprecipitates was assayed 24 hrs
later. Western blot of total cell lysates with anti- PKCf antibody
verified overexpression of PKCf (T/A)4 (Fig. 5A). The transfected
PKCf co-migrated with the faster-migrating endogenous band,
supporting our earlier conclusion regarding its identity. PKCf (T/
A)4 suppressed CSF-1-stimulated HA-Erk activity (average inhibi-
tion of 76%64%, n=3, p,0.005) but it also suppressed PMA-
induced ERK activity by an equivalent amount (Fig. 5A). The lack
of specificity of the dominant-inhibitory actions of PKCf (T/A)4
towards the different PKC isoforms has been observed by others
and may be a common property of many dominant-negative PKC
mutants, reflecting a common mechanism of activation (Thr 410
phosphorylation by PDK-1) and sequestration of upstream
activators [30]. Nevertheless, since CSF-1 dependent MEK-Erk
activationdidnotdependonPMA-sensitivePKCs,theinhibitionby
dominant-negative PKCf therefore supports a role for PKCf.
In another approach to investigate if PKCf could contribute to
ERK activation, we used HA-tagged constitutively active PKCf
containing only the catalytic domain (PKCfcat). First, we
determined the kinase activity of transfected HA-tagged wildtype
(WT) and PKCfcat. As shown (Fig. 5B), only HA immunopre-
cipitates from cells transfected with PKCf but not with control
vector showed kinase activity. PKCfcat exhibited considerably
higher kinase activity when compared to WT- PKCf. PKCfcat
was transiently co-expressed with Myc-tagged Erk (Fig. 5B). MBP
kinase assay was performed on Myc immunoprecipitates and
showed that basal ERK activity was increased in cells transfected
with PKCfcat over that with empty vector control (Fig. 5B, fold
increase over vector control in unstimulated cells: experiment
#1=1.8, experiment #2=3.5). Although the increase was not
marked, it is consistent with published reports [47] and show that
in 32D.R cells, PKCf can regulate Erk activity. The findings with
dominant-negative and constitutively active PKCf support the
PKC inhibitor studies and implicate a role for PKCf in CSF-1
stimulated Erk activation.
TNFa but not CSF-1 activates the NF-kB pathway in
32D.R cells
Since PKCf appeared to play a role in CSF-1 mediated
mitogenesis and PKCf has been shown to activate the NF-kB
pathway which regulates genes involved in cell proliferation [48],
we examined if CSF-1 stimulated NF-kB activity. Transient
transfection with an NF-kB reporter did not show any detectable
activity (data not shown). To confirm this finding, we established a
stable 32D.R cell line expressing an NF-kB reporter. Although
TNFa robustly stimulated NF-kB reporter activity, CSF-1 had no
effect (Fig. 6). These findings demonstrated that PKCf does not
use the NF-kB pathway to promote CSF-1 induced mitogenesis.
Overexpression of WT- PKCf in 32D.R cells increased Erk
activity and sensitivity to CSF-1 induced proliferation
We established a stable cell line overexpressing WT- PKCf
(Fig. 7A). We were unsuccessful in establishing stable lines
expressing PKCfcat, suggesting that unregulated PKCf activity
may be detrimental to 32D.R cell survival. CSF-1 dose response
MTS results showed a shift in EC50 from 0.58 nM in vector-
transfected cells to 0.36 nM in WT- PKCf overexpressing cells
(p=0.0005) indicating enhanced sensitivity to CSF-1 provoked
mitogenesis. Importantly, CSF-1 induced Erk phosphorylation was
also increased in cells overexpressing WT- PKCf and this
enhancement was observed at 5 min and beyond (Fig. 7B).
Altogether, our results in 32D.R cells support a role for PKCf
mediating a part of the CSF-1 dependent Erk activity and
mitogenic response.
PKC inhibition paradoxically enhanced CSF-1 induced
MEK-Erk activity in BMMs
Under the influence of CSF-1, myeloid progenitors differentiate
to macrophages [1]. We were interested in the role of PKCf in
CSF-1 dependent Erk activation and proliferation in macrophag-
es. However, the 32D.R cell line does not differentiate to mature
macrophages in response to CSF-1 as demonstrated by flow
cytometric analysis (Fig. S1), and the absence of adherence to
plastic. We therefore utilized bone marrow derived macrophages
(BMMs). Although it would have been preferable to use a single
system to assess the role of PKC in progenitors and mature
macrophages, obtaining primary myeloid progenitors in sufficient
numbers for biochemical assays of the type described is
impractical. BMMs were starved in the absence of CSF-1 for
12 hr and then re-stimulated with CSF-1. At concentrations of
GF109203X and Go ¨ 6850 that had significantly inhibited CSF-1
induced MEK-Erk activity in 32D.R myeloid progenitors, we saw
a paradoxical increase in CSF-1 dependent MEK and Erk
phosphorylation in BMMs (Fig. 8A). Pretreatment with the PKCf
pseudosubstrate peptide resulted in a similar increase in MEK and
Erk phosphorylation. To determine if starvation conditions could
be a factor, we starved BMMs in serum-free media for 6 hrs before
re-stimulation with CSF-1 in the presence or absence of
GF109203X. A similar increase in MEK-Erk phosphorylation
was observed (Fig. 8B). In BMMs, PKCf Thr 410 phosphory-
lation was minimally increased by CSF-1 treatment (Fig. 8C).
These data indicate that PKCs impact the MEK-Erk pathway
differentially in mature macrophages compared to progenitors.
Since the increase in MEK-Erk phosphorylation was also seen at
inhibitor concentrations that target conventional and novel PKCs,
it would appear that PKC inhibitors are directed at a common
mechanism that normally negatively regulates the MEK-Erk
pathway.
Figure 6. CSF-1 does not activate an NF-kB luciferase reporter
in 32D.R cells. A 32D.R line stably expressing an NF-kB luciferase
reporter was treated as indicated and lysates subjected to a luciferase
assay at 6 h or 20 h after stimulation. CSF-1 was used at 5 nM and TNFa
at 20 ng/mL. Inhibitors were used at GF109203X (10 mM), Ro-3108220
(1 mM) and Go ¨ 6893 (5 mM).
doi:10.1371/journal.pone.0025580.g006
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proliferation
In the absence of CSF-1, BMMs undergo cell death within 24 h
hence all of our proliferation assays were performed in the
presence of CSF-1. Treatment of BMMs with the PKCf
pseudosubstrate peptide reduced proliferation by a small amount
(15–20%) as assessed by MTS activity and cell counts (Fig. 9A
and B). To determine if PKCf synergized with other pathways to
promote proliferation in BMMs, we used U0126 to inhibit MEK-
Erk and LY294002 to inhibit PI3K. After 4 days, U0126 or
LY294002 treatment reduced CSF-1 supported mitogenesis by
40%; including the PKCf pseudosubstrate did not lead to
additional reduction (Fig. 9C). These data indicate that PKCf
does not have a major role in supporting proliferation in BMMs.
We also investigated the impact of GF109203X and Go ¨ 6983
inhibition. In contrast to 32D.R cells, GF109203X was more
potent than Go ¨ 6938 in reducing mitogenesis (Fig. 9A and 9C). At
1 mM, GF109203X reduced mitogenesis by 40% compared to
,10% for 1 mMG o ¨ 6850, underscoring the contribution of
cellular factors in addition to IC50 to long-term effects of PKC
inhibitors. Interestingly, $10 mM GF109203X dramatically
reduced proliferation, not seen in 32D.R cells, suggesting that
GF109203X may target an as yet unknown protein in BMMs. At
10 mM, Go ¨ 6983 synergized with either U0126 or LY294002 to
inhibit proliferation, with the combination of LY294002 and Go ¨
6983 being more potent. These data suggest that in contrast to
32D.R myeloid progenitors, PKCf has less of a role in promoting
proliferation in BMMs but conventional/novel PKCs cooperate
with MEK-Erk and PI3K to support BMM proliferation.
Discussion
PKCs play pleiotropic roles in many cellular processes. How
PKCs contribute to CSF-1 dependent functions is not well
characterized. In this study, we addressed two questions using the
32D.R myeloid progenitor cell line and primary mouse BMMs :
1) Is PKC an activator of the MEK-Erk pathway; 2) Does PKC
contribute towards CSF-1 dependent proliferation? In 32D.R
cells, we presented evidence in support of a role for the atypical
PKC, PKCf, in CSF-1 dependent activation of MEK-Erk and
mitogenesis. (1) Downregulation of PKCa and PKCd by chronic
phorbol ester treatment had no effect on CSF-1 mediated MEK-
Erk activation, excluding a role for these enzymes. (2) The novel
PKC, PKCe, which was expressed in these cells, was partially
Figure 7. WT-PKCf overexpression enhances CSF-1 dependent proliferation and Erk phosphorylation. (A) (left) PKCf protein expression
in 32D.R cells transfected with empty vector (pEF) or WT- PKCf. (right) CSF-1 dose responsive MTS assay. The two curves were statistically different.
CSF-1 concentrations were in nM. (B) Erk phosphorylation in control 32D.R cells (C) or 32D.R cells overexpressing WT- PKCf (WT) in response to CSF-1
stimulation for the indicated times. Lysates were immunoblotted with anti-phospho-Erk (top) or total Erk (bottom) antibodies. Phosphorylation
changes are calculated as described in Figure 2 relative to that determined for control cells stimulated by CSF-1 for 1 min (fold increase is 4.6).
doi:10.1371/journal.pone.0025580.g007
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stimulated by CSF-1 in a membrane translocation assay and was
unlikely to be involved. (3) PKCf kinase activity and Thr 410
phosphorylation were increased by CSF-1. (4) At concentrations
of GF109203X and Go ¨ 6983 that should inhibit the kinase
activity of PKCf, CSF-1 induced MEK-Erk activity was
significantly reduced. This conclusion was supported by the
results of transient overexpression of dominant-negative or
constitutively active PKCf on Erk activity. Moreover, stable
overexpression of WT- PKCf increased the magnitude and
duration of Erk activation. (5) At concentrations of PKC
inhibitors that reduced CSF-1-supported Erk activation, mito-
genesis was also suppressed. This was corroborated using a PKCf
specific inhibitory peptide and by stable overexpression of WT-
PKCf. In contrast, in BMMs, PKC inhibition increased CSF-1
dependent MEK-Erk activation indicating a different role for
PKCs compared to immature cells. PKCf was not a major
contributor to proliferation but conventional/novel PKCs
Figure 8. The effect of PKC inhibitors on MEK-Erk activation in bone marrow derived macrophages. (A) BMMs were starved in the
absence of CSF-1 for 12 h, inhibitors were added or not for 1 h followed by stimulation with 5 nM CSF-1. Inhibitor concentrations used were:
GF109203X (GF) at 0.1, 1 and 10 mM; Go 6983 (Go) at 0.1, 1 mM and PKCf-PS peptide at 10 mM. Lysates were immunoblotted with phospho-Erk and
total Erk antibodies (top 2 panels) or with phospho-MEK and total MEK antibodies (bottom 2 panels). Phosphorylation changes are shown as a
percent of that determined for CSF-1 stimulation at 5 min in the absence of inhibitors. For the data shown, CSF-1 stimulated MEK and Erk by 46- and
62-fold over untreated cells. (B) BMMs were starved in serum free media for 6 h, 1 or 10 mM GF109203X was added as shown followed by CSF-1
stimulation for 5 min. (C) PKCf phosphorylation. (Top) PKCf was immunoprecipitated with a rabbit polyclonal antibody and blotted with an antibody
that recognizes PKCf phospho-Thr 410. (Bottom) The blot was stripped and reprobed with a monoclonal antibody that recognizes PKCf. Shown are
representative results from one of two experiments performed. Immunoblot images in Figure 8 were captured digitally using the AlphaImager Gel
Imaging System (FluorChem Q, Cell Biosciences, Santa Clara, CA).
doi:10.1371/journal.pone.0025580.g008
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support mitogenesis.
Previously, we showed in 32D.R cells that CSF-1 activated
MEK-Erk using both an A-Raf-dependent and an A-Raf
independent pathway that did not involve c-Raf-1 [16]. Since
PKC inhibitors had no effect on A-Raf activity, we believe that
PKCf activated MEK-Erk independent of A-Raf. CSF-1
increased Thr 410 phosphorylation on PKCf which is PDK1
mediated [26,49]. PDK1 is constitutively activated but depends on
PI3K for membrane localization [43]. Although we did not detect
CSF-1-induced translocation of PKCf to the membrane, about
12% of total PKCf was found in the particulate fraction and this
population is poised to interact with PDK1. PDK1 is also
distributed throughout the cell [43] so that PDK-1 mediated
phosphorylation of the active site in PKCf can also occur in the
cytosol. Regardless of where PKCf is phosphorylated in 32D.R
cells, CSF-1 induced a significant increase in Thr 410 phosphor-
ylation. How PKCf activates MEK-Erk is not well understood.
The epidermal growth factor induces the association of PKCf with
MEK5, a pathway that is important for mitogenic signaling [50].
However the docking site identified in MEK5 for PKCf is absent
in MEK1/2, raising the question of whether there is another
MEK kinase that is stimulated by PKCf.
In BMMs, inhibitors that target conventional/novel/atypical
PKCs all appeared to upregulate CSF-1 supported MEK-Erk
activity. Our observations are consistent with PKC inhibition
relieving negative regulation of MEK-Erk signaling. MAPKs and
MEK1/2 are dephosphorylated by dual specific phosphatases
(DUSPs) and protein phosphatases 2A respectively [51]. PKCs
could promote the activation of these phosphatases. Our findings
extend those reported in an earlier study on BMMs where it was
found that CSF-1 induction of DUSP1 (MKP-1) is dependent on
PKCe [52]. These authors reported that GF109203X pretreat-
ment prolonged Erk phosphorylation but did not enhance its
degree of activation, which is consistent with the timeframe of
DUSP1 induction. In contrast, we saw an increase in MEK-Erk
activation at 5 min that is already dissipated at 30 min. Since
DUSP1 is induced closer to 30 min than 5 min, DUSP1 is unlikely
to be responsible for the increase in Erk phosphorylation in the
presence of PKC inhibitors; also DUSP1 is not known to
dephosphorylate MEK. A second possibility is that PKC activity
is necessary for the action of a negative regulator upstream of
MEK. The negative regulator could be directed at the MEK
kinase or a scaffold such as KSR that brings the members of the
MEK kinase-MEK-Erk module into close proximity [53]. Our
findings contrast with those in the BAC1.2F5 macrophage cell line
where no effect of GF109203X on CSF-1 stimulated MEK and
Erk kinase activity was observed [54]. Possibly this could reflect a
difference in cell type (primary versus cell line) or assay
(phosphorylation versus kinase activity), although we have found
that dual phosphorylation at the TEY motif as detected by the
antibody used in this study to track kinase activity faithfully. More
extensive investigations will be required to determine the
mechanism of PKC input into Erk activation in BMMs.
Our data show that PKCf contributes towards CSF-1 mediated
mitogenesis in 32D.R cells, in part through the MEK-Erk
pathway. Since PKCf is known to activate the NF-kB pathway
[25], it was surprising to find that CSF-1 did not transactivate an
NF-kB reporter construct stably expressed in 32D.R cells whereas
TNFa was a potent activator in these cells. PKCf is thought to
phosphorylate the RelA subunit of NF-kB at Ser311 and the
phosphorylation assists in setting up CBP recruitment [55].
However other activation steps are necessary and presumably,
were not stimulated by CSF-1 in 32D.R cells. In BMMs, PKCf
does not appear to play a major role to support CSF-1 mediated
proliferation. Conventional/novel PKCs are more important and
PKC inhibitors synergize with MEK and PI3K inhibition in
reducing proliferation, indicating PKC, MEK and PI3K to be
working on parallel pathways. The impact of PKC inhibitors on
mitogenesis in BMMs may have been offset by their simultaneous
promotion of MEK-Erk activation, so that the actual contribution
of PKC to mitogenesis in BMMs may have been more significant
than the data showed. In addition to proliferation, different groups
have investigated PKC action in other aspects of mononuclear
phagocyte function. PKCf is said to be important in CSF-1
induced chemotaxis in macrophages [29], RANKL/CSF-1
mediated bone remodeling [56] and PKCd is important for
LPS-induced soluble Flt-1 expression [57]. Additionally PKCs
could be involved in myeloid differentiation, primarily involving
PKCd [27,58].
In summary, we have identified PKCf as a crucial activator of
MEK-Erk in the CSF-1 signaling pathway in myeloid progenitors.
In mature macrophages, PKCf and other PKC members appear
to target a common negative regulator of CSF-1-dependent MEK-
Erk activity. These findings indicate that the cellular context of
CSF-1 signaling must be considered and the role of different PKC
subclasses in macrophages warrants an in-depth investigation.
Supporting Information
Figure S1 32D.R cells have an immature immunophe-
notype that is different from bone marrow derived
macrophages (BMM). 32D.R cells were cultured in the
presence of CSF-1 or IL-3 before analysis. Day 7 BMMs (see
Methods) were used. (A) Forward and side scatter profile. (B)
Staining of 32D.R with isotype control antibodies (isotype), or with
CD31 and CD11b. (C) Staining of 32D.R with isotype control
antibodies (isotype), or with CD31 and Ly6C. (D) Staining of
BMMs with CD31, CD11b or with CD31, Ly6C.
(TIF)
Methods S1 Supplementary methods.
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Figure 9. The effect of PKC inhibitors on bone marrow derived macrophage proliferation. (A) BMMs were treated with the inhibitors
indicated in the presence of 5 nM CSF-1 and MTS activity assayed at 48 h, 72 h and 96 h. Similar results were obtained with 0.25 nM and 1 nM CSF-1
(not shown). (B) BMMs were treated with PKCf PS peptide inhibitor in the presence of CSF-1 and cell counts determined at 96 h. (C) The experiment
was performed as described in (A). The concentrations shown are in mM. U0126, 10 mM; LY, 5 mM LY294002.
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